Agilent Launches AI-Powered xCELLigence RTCA eSight AI Module for Label-Free Live-Cell Imaging Analysis
核心洞察
Agilent Technologies (搜索) has launched xCELLigence RTCA eSight (搜索) AI, a new AI-powered software module that simplifies label-free live-cell imaging analysis by replacing manual cell segmentation with automated workflows.
The module enhances the dual-readout xCELLigence RTCA eSight (搜索) platform by combining AI-driven image analysis with impedance measurements from the same cells in a single experiment.
The one-click automated workflow is designed to reduce variability across users, decrease analysis time, and lower training requirements for biopharma researchers.
Agilent Technologies (搜索) Inc. has announced the launch of xCELLigence RTCA eSight (搜索) AI, a new AI-powered software module designed to simplify label-free live-cell imaging analysis for biopharma researchers. The software upgrade enhances the unique dual-readout capabilities of the Agilent xCELLigence RTCA eSight instrument by integrating AI-driven cell imaging analysis with impedance measurements, enabling researchers to gain imaging and impedance insights from the same cells in the same experiment with greater speed and confidence.
The launch comes as Agilent continues to strengthen its long-term growth prospects through product innovation and expanding AI-enabled laboratory software and automation capabilities, supported by healthy demand across the pharmaceutical, diagnostics and advanced materials markets.
Addressing Variability in Traditional Cell Segmentation
Traditional cell segmentation workflows rely on time-consuming and subjective manual setup and analysis steps that increase variability, error and rework, slowing experimental timelines while also requiring a higher level of experimental expertise to achieve consistent results. As biopharma research increasingly demands more complex experiments, higher throughput and greater consistency, integrated workflows have become key to efficient scientific progress.
The new xCELLigence RTCA eSight (搜索) AI module addresses these challenges by reducing manual cell segmentation steps and parameter tuning, supporting more consistent results. The streamlined, integrated approach is expected to provide biopharma researchers with a more complete view of cell behavior while reducing variability across users and conditions.
One-Click Automated Workflow
The software replaces manual cell segmentation and subjective parameter tuning with a one-click automated workflow, helping researchers generate more consistent and reproducible results while reducing analysis time and lowering training requirements. Designed for drug discovery and high-throughput biopharma research, the software is expected to accelerate scientific workflows, improve laboratory productivity and expand adoption of Agilent's integrated cell analysis platform.
AI-driven imaging analysis can help reduce variability across users while decreasing time spent on manual analysis, a critical advantage as pharmaceutical and biotechnology companies increasingly digitize research workflows and accelerate drug discovery.
Broader AI Strategy and Market Position
Agilent continues to expand its AI capabilities across laboratory software, automation and digital workflows. During the second quarter of fiscal 2026, AI was highlighted as a key long-term growth driver, with increasing customer adoption and continued investments in digital laboratory solutions expected to support sustainable growth. The company is integrating AI across its analytical instruments, laboratory informatics and automation solutions to enhance scientific workflows and operational efficiency.
Agilent's integrated software ecosystem, led by its OpenLab and xCELLigence platforms, combines analytical instruments, software and laboratory automation to improve productivity, reduce manual intervention and deliver more consistent scientific results. The company is further expanding its digital laboratory capabilities through the announcement of the China Innovation Center in June 2026, which focuses on AI, automation and digital laboratory technologies to enable next-generation smart laboratories.
Financial Outlook
Agilent's improving demand environment, expanding AI software portfolio and continued product innovation are expected to benefit the company's top-line growth. For the third quarter of fiscal 2026, Agilent expects revenues to be in the range of $1.83 billion to $1.85 billion, implying 5.0% to 6.5% reported growth and 4.4% to 5.9% core growth. The Zacks Consensus Estimate for third-quarter fiscal 2026 revenues is pegged at $1.84 billion, indicating year-over-year growth of approximately 6.02%.
Agilent shares have lost 5.2% in the year-to-date period, underperforming the Zacks Medical industry's 2.8% growth, reflecting cautious laboratory spending and a challenging macroeconomic environment. However, the company's continued investment in AI-enabled laboratory solutions is expected to support long-term software and biopharma growth.